ephedrine sulfate · Nexus · NDA 213407
Emerphed
Earliest generic entry, as listed · earliest of 2 marketed strengths
16 May 2040
Blocked by patent: US 11090278, US 11241400, US 11464752, US 11478436, US 11571398.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11090278 | use U-3183 · sets the listed date | 16 May 2040 |
| US 11241400 | use U-3183 · sets the listed date | 16 May 2040 |
| US 11464752 | drug product · sets the listed date | 16 May 2040 |
| US 11478436 | use U-3183 · sets the listed date | 16 May 2040 |
| US 11571398 | use U-3183 · sets the listed date | 16 May 2040 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 213407 · 001 · RLD | solution, intravenous | 50MG/10ML (5MG/ML) | 16 May 2040 |
| 213407 · 002 · RLD | solution, intravenous | 25MG/5ML (5MG/ML) | 16 May 2040 |